Imatinib

Generic Name
Imatinib
Brand Names
Gleevec, Glivec, Imatinib Teva, Imatinib Accord
Drug Type
Small Molecule
Chemical Formula
C29H31N7O
CAS Number
152459-95-5
Unique Ingredient Identifier
BKJ8M8G5HI
Background

Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication

Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Phase 3
Completed
Conditions
Chronic Myeloid Leukemia
Interventions
Drug: Imatinib
Drug: Nilotinib
First Posted Date
2011-01-12
Last Posted Date
2016-04-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
267
Registration Number
NCT01275196
Locations
🇨🇳

Novartis Investigative Site, Shanghai, China

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Phase 1
Withdrawn
Conditions
Chronic Myeloid Leukemia
First Posted Date
2010-08-26
Last Posted Date
2015-05-15
Lead Sponsor
University of Michigan Rogel Cancer Center
Registration Number
NCT01188889
Locations
🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

First Posted Date
2010-08-25
Last Posted Date
2016-09-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
173
Registration Number
NCT01188278

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Phase 3
Completed
Conditions
Gastrointestinal Stromal Tumors
Interventions
Drug: Placebo
Drug: Imatinib
First Posted Date
2010-06-29
Last Posted Date
2020-01-14
Lead Sponsor
Asan Medical Center
Target Recruit Count
81
Registration Number
NCT01151852
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

Phase 1
Completed
Conditions
Neurofibromas
Neurofibromatosis
Interventions
Drug: Gleevec
First Posted Date
2010-06-09
Last Posted Date
2017-07-02
Lead Sponsor
Kent Robertson
Target Recruit Count
21
Registration Number
NCT01140360
Locations
🇺🇸

Riley Hospital for Children, Indianapolis, Indiana, United States

Study to Evaluate Imatinib in Desmoid Tumors

Phase 2
Completed
Conditions
Aggressive Fibromatosis
Desmoid Tumor
Interventions
Drug: Imatinib
First Posted Date
2010-06-07
Last Posted Date
2017-05-03
Lead Sponsor
Heidelberg University
Target Recruit Count
39
Registration Number
NCT01137916
Locations
🇩🇪

University of Heidelberg, Mannheim University Medical Center, Mannheim, Germany

Treatment of Polycythemia Vera With Gleevec

Phase 2
Completed
Conditions
Polycythemia Vera
Interventions
Drug: Gleevec
First Posted Date
2010-05-11
Last Posted Date
2010-05-17
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
36
Registration Number
NCT01120821
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Phase 3
Terminated
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Imatinib
Drug: Placebo
First Posted Date
2010-05-06
Last Posted Date
2015-08-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
144
Registration Number
NCT01117987
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

Late Chronic Phase Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: Gleevec
First Posted Date
2010-03-25
Last Posted Date
2016-05-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
47
Registration Number
NCT01092741
Locations
🇺🇸

The University Of MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

First Posted Date
2010-01-13
Last Posted Date
2012-09-25
Lead Sponsor
Royal Marsden NHS Foundation Trust
Target Recruit Count
36
Registration Number
NCT01048320
Locations
🇬🇧

Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy